Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22735677 | 0.86 | KMT2A (0.36) | KMT2AP2RX7RXFP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22734477 | 0.84 | TP53 (0.36) | KMT2AP2RX7ALDH1A1TP53 | |
| SCHEMBL22734583 | 0.79 | KMT2A (0.38) | KMT2ARXFP1ALDH1A1JAK2JAK1 | |
| SCHEMBL22734659 | 0.77 | KMT2A (0.37) | KMT2AALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL22735699 | 0.74 | BRD4 (0.59) | — | |
| SCHEMBL22735702 | 0.72 | CTSK (0.38) | ALDH1A1CYP3A4 | |
| SCHEMBL22735938 | 0.72 | CTSK (0.38) | ALDH1A1CYP3A4 | |
| SCHEMBL22734504 | 0.70 | CTSS (0.35) | KMT2AALDH1A1TP53CYP3A4 | |
| SCHEMBL22105567 | 0.68 | TSHR (0.45) | RXFP1ALDH1A1SMN1; SMN2GAATSHR | |
| SCHEMBL22734715 | 0.67 | BRD4 (0.61) | KMT2ASMN1; SMN2TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | BET1, BRD4, BRD3 | KMT2A 941/4885P2RX7 1955/4885RXFP1 1769/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | KMT2A 1009/4885P2RX7 1791/4885RXFP1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.